BRIEF published on 12/15/2025 at 07:10, 10 months 20 days ago Piramal Pharma Solutions Achieves High Net Promoter Score Operational Excellence Net Promoter Score Customer Loyalty Piramal Pharma Competitive Positioning
PRESS RELEASE published on 12/15/2025 at 07:05, 10 months 20 days ago Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score Piramal Pharma Solutions achieves impressive Net Promoter Score (NPS) of 55, surpassing industry averages, reflecting commitment to excellence and stakeholder centricity Operational Excellence Net Promoter Score Piramal Pharma Solutions NPS Stakeholder Centricity
BRIEF published on 11/26/2025 at 20:30, 11 months 8 days ago Piramal Pharma Solutions garantit la conformité aux réglementations sur les nitrosamines Normes Réglementaires Sécurité Pharmaceutique Conformité Aux Nitrosamines Capacités De Test Solutions Pharmaceutiques Piramal
BRIEF published on 11/26/2025 at 20:30, 11 months 8 days ago Piramal Pharma Solutions Ensures Compliance with Nitrosamine Regulations Regulatory Standards Piramal Pharma Solutions Nitrosamine Compliance Pharmaceutical Safety Testing Capabilities
PRESS RELEASE published on 11/26/2025 at 20:25, 11 months 8 days ago Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities Piramal Pharma Solutions achieves regulatory compliance for nitrosamine impurities, ensuring safety & adherence to global guidelines, enhancing capabilities & operational excellence Regulatory Compliance Operational Excellence Patient Safety Piramal Pharma Solutions Nitrosamine Impurities
BRIEF published on 11/19/2025 at 09:00, 11 months 15 days ago L'usine de Piramal Pharma à Grangemouth obtient les certifications BPF mises à jour de la MHRA. Développement ADC Piramal Pharma Certification BPF Installations De Grangemouth Approbation De La MHRA
BRIEF published on 11/19/2025 at 09:00, 11 months 15 days ago Piramal Pharma's Grangemouth Facility Secures Updated MHRA GMP Certifications ADC Development GMP Certification MHRA Approval Piramal Pharma Grangemouth Facility
PRESS RELEASE published on 11/19/2025 at 08:55, 11 months 15 days ago Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK receives updated MHRA GMP certificates, highlighting commitment to quality and regulatory excellence Drug Development Piramal Pharma Solutions Bioconjugates Facility MHRA GMP Certificates Grangemouth
BRIEF published on 10/30/2025 at 06:30, 1 year ago Piramal Pharma Solutions Partners with IntoCell to Enhance Bioconjugate Capabilities ADC Development Pharmaceutical Collaboration Piramal Pharma IntoCell Bioconjugates
BRIEF published on 10/30/2025 at 06:30, 1 year ago Piramal Pharma Solutions s'associe à IntoCell pour renforcer ses capacités en matière de bioconjugaison. Développement ADC Collaboration Pharmaceutique Piramal Pharma IntoCell Bioconjugués
Published on 11/04/2026 at 23:10, 3 hours 7 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 3 hours 17 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 4 hours 2 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 4 hours 12 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 00:02, 2 hours 14 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 6 hours 35 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 51 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 7 hours 34 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 8 hours 11 minutes ago Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 18:00, 8 hours 16 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 8 hours 16 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 8 hours 33 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
